The Impact of Late Secondary Hyperparathyroidism on Mortality in COVID-19 Patients: A Longitudinal Study

Sima Hashemipour; Sabereh Afshar; Somaieh Kiani; Pouria  Shahsavari; Milad  Badri; Arf Ghobadi; Seyyed Mohammad Reza  Hadizadeh Khairkhahan

Journal of Inflammatory Diseases

The Official Journal of Qazvin University of Medical Sciences

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Editors & Boards Indexing and Listing Sources Reviewer and AE Registration Form Journal Metrics Open Peer Review (OPR)Publication Ethics and Publication Malpractice Statement Support Contact Us

Authors Guide Submit Manuscript

The Impact of Late Secondary Hyperparathyroidism on Mortality in COVID-19 Patients: A Longitudinal Study

Author(s):

Sima Hashemipour¹,

Sabereh Afshar^1,*,

Somaieh Kiani¹,

Pouria Shahsavari ¹,

Milad Badri ²,

Arf Ghobadi¹,

Seyyed Mohammad Reza Hadizadeh Khairkhahan¹

1Metabolic Diseases Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran.

2Medical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.

Journal of Inflammatory Diseases:Vol. 26, issue 2; 67-78

Article type:Research Article

How to Cite:Sima HashemipourSabereh AfsharSomaieh KianiPouria Shahsavari Milad Badri Arf GhobadiSeyyed Mohammad Reza Hadizadeh Khairkhahanet al.The Impact of Late Secondary Hyperparathyroidism on Mortality in COVID-19 Patients: A Longitudinal Study.J Inflamm Dis.26(2):e156311.

Abstract

Background: Adverse effects of high parathormone hormone (PTH) in critical illness have been described in some studies. Objective: The relationship between high PTH levels with mortality in hospitalized patients with COVID-19 was evaluated in the present study. Methods: A total of 123 patients were included in the study. The patients were evaluated in phase 1 (on admission) and phase 2 (days 4-6 of hospitalization). The patients were categorized into four groups based on the PTH status in both phases: normal PTH1/normal PTH2 (group 1), high PTH1/normal PTH2 (group 2), high PTH1/high PTH2 (group 3), and normal PTH1/high PTH2 (group 4). The multiple logistic regression analysis was performed to examine the independent association of late hyperparathyroidism with mortality. After excluding ineligible participants, 115 patients in phase 1 and 96 patients in phase 2 (days 4-6 of hospitalization) were evaluated. Findings: The level of phase 2 PTH in non-survivors was significantly higher than in survivors (57.5±40.9 pg/mL vs. 27.6±16.2 pg/mL, P=0.001). The mortality rate was significantly higher in high-PTH groups in phase 2 compared to normal-PTH groups in this phase (50% and 42.9% in groups 3 and 4 vs. 6.6% and 18.2% in PTH groups 1 and 2, respectively, P=0.007). Late hyperparathyroidism was associated with 11.4 times higher mortality risk (95% CI: 2.3-56.1, P=0.003). Conclusion: Late hyperparathyroidism remained a significant predictor of mortality after adjusting for the main PTH secretion modulators and disease severity. Late hyperparathyroidism is an independent and strong risk factor for mortality in COVID-19. Further studies are necessary to clarify the mechanisms involved.

Keywords

COVID-19

Parathormone hormone (PTH) level

Mortality

Late hyperparathyroidism

Longitudinal study

References

1.
A. Kelly and M. A. Levine et al (2013) Hypocalcemia in the critically ill patient. J. Intensive Care Med 28(3), 166-177.
2.
G. P. Zaloga and B. Chernow et al (1987) The multifactorial basis for hypocalcemia during sepsis: studies of the parathyroid hormone-vitamin D axis. Ann Intern Med 107(1), 36-41.
3.
J. Liu, P. Han, J. Wu, J. Gong et al (2020) Prevalence and predictive value of hypocalcemia in severe COVID-19 patients. J Infect Public Health 13(9), 1224-1228.
4.
S. Bennouar, A.B. Cherif, A. Kessira et al (2021) Vitamin D deficiency and low serum calcium as predictors of poor prognosis in patients with severe COVID-19. J Am Coll Nutr 40(2), 104-110.
5.
S Hashemipour, S Kiani, P Shahsavari et al (2022) Hypocalcemia in hospitalized patients with COVID-19: roles of hypovitaminosis D and functional hypoparathyroidism. J Bone Miner Metab: 1-7. doi.org/10.1007/s00774-022-01330-w.
6.
LD Filippo, AM Formenti, P Rovere-Querini et al (2020) Hypocalcemia is highly prevalent and predicts hospitalization in patients with COVID-19. Endocrine 68(3), 475-478.
7.
J W Martha, A Wibowo, R Pranata et al (2021) Hypocalcemia is associated with severe COVID-19: A systematic review and meta-analysis. Diabetes Metab Syndr Clin Res Rev 15(337-342). doi.org/10.1016/j.dsx.2021.01.003.
8.
J Sun, W Zhang, LZou et al (2020) Serum calcium as a biomarker of clinical severity and prognosis in patients with coronavirus disease 2019. Aging (Albany NY) 6;12(12) (2020), 11287.
9.
S Bennouar, A B Cherif, A Kessira et al (2021) Vitamin D deficiency and low serum calcium as predictors of poor prognosis in patients with severe COVID-19. J Am Coll Nutr 40(2), 104-110.##.
10.
Murthi, M., et al et al (2021) Association of hypocalcemia with in-hospital mortality and complications in patients with acute pulmonary embolism: results from the 2017 Nationwide Inpatient Sample. BMC Pulm Med 21(1), 1-6.##.
11.
T Steele, R Kolamunnage-Dona, C Downey et al (2013) Assessment and clinical course of hypocalcemia in critical illness. Critical Care 17(3), 1-10.
12.
B Torres, P Alcubilla, A Gonzlez-Cordn et al (2021) Impact of low serum calcium at hospital admission on SARS-CoV-2 infection outcome. Int J Infect Dis 104, 164-168.##.
13.
W T Davis, P C Ng, K L Medellin et al (2022). Association of Hypocalcemia With Mortality of Combat Casualties With Brain Injury and Polytrauma Transported by Critical Care Air Transport Teams. Mil Med, doi.org/10.1093/milmed/usac029.##.
14.
F Carlstedt, L Lind, J Rastad et al (2018). Association of admission serum levels of vitamin D, calcium, Phosphate, magnesium and parathormone with clinical outcomes in neurosurgical ICU patients. Sci Rep 8(1), 1-8.##.
15.
J Hu, Z Luo, X Zhao et al (2013). Changes in the calcium-parathyroid hormone-vitamin d axis and prognosis for critically ill patients: a prospective observational study." PloS one 8(9), e75441.
16.
SH Ardehali, S Dehghan, AR Baghestani et al (2018) Association of admission serum levels of vitamin D, calcium, Phosphate, magnesium and parathormone with clinical outcomes in neurosurgical ICU patients. Sci Rep 8(1), 1-8.
17.
S. Hashemipour, S. Kiani, P. Shahsavari et al (2022) Contributing factors for calcium changes during hospitalization in COVID-19: A Longitudinal Study. Int J Endocrinol Metab 20(2). 10.5812/ijem-122378.
18.
D Goltzman, CJ Rosen, JE Mulder et al (2020). Diagnostic approach to hypocalcemia. Up To Date, Sep;69(3):485-95.
19.
J Chris Gallagher, A J Sai et al (2010) Vitamin D insufficiency, deficiency, and bone health, Oxford University Press. J Clin Endocrinol Metab 95, 2630-2633. https://doi.org/10.1210/jc.2010-0918.
20.
E Alemzadeh, E Alemzadeh, M Ziaee et al (2021). The effect of low serum calcium level on the severity and mortality of Covid patients: A systematic review and metaanalysis. Immun Inflamm Dis 9(4), 1219-1228.
21.
P Nair, P Lee, C Reynolds et al (2013)Significant perturbation of vitamin Dparathyroidcalcium axis and adverse clinical outcomes in critically ill patients. Intensive Care Med 39(2), 267-274.
22.
R Baczynski, R Kohan, M Magott et al (1985) Effect of parathyroid hormone on myocardial energy metabolism in the rat. Kidney Int 27(5), 718-725.
23.
KD Schlter, HM Piper et al (1998) Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res 37(1), 34-41.
24.
Rostand, S. G. and T. B. Dreke (1999) Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 56(2), 383-392.
25.
Smogorzewski, M et al (1995) PTH, chronic renal failure and myocardium. Miner Electrolyte Metab 21(1-3), 55-62.
26.
SJ Brown, MD Ruppe, LS Tabatabai et al (2017) The parathyroid gland and heart disease. Methodist Debakey Cardiovasc 13(2), 49.
27.
Y Jiang, A Yoshida, C Ishioka et al (1992) Parathyroid hormone inhibits immunoglobulin production without affecting cell growth in human B cells. Clin Immunol 65(3), 286-293.
28.
Massry, S. G. and M. Smogorzewski (2001) Dysfunction of polymorphonuclear leukocytes in uremia: role of parathyroid hormone Kidney Int 59, S195-S196.
29.
AS Geara, MR Castellanos, C Bassil et al (2010) Effects of parathyroid hormone on immune function. Clin Dev Immunol. 10.1155/2010/418695.
30.
JM Alexiewicz, M Smogorzewski, M Klin et al (1995) Effect of treatment of hemodialysis patients with nifedipine on metabolism and function of polymorphonuclear leukocytes. Am J Kidney Dis 25(3), 440-444.
31.
WH Hrl, M Haag-Weber, B Mai et al (1995) Verapamil reverses abnormal [Ca2+] i and carbohydrate metabolism of PMNL of dialysis patients. Kidney Int 47(6), 1741-1745.
32.
JM Alexiewicz, M Smogorzewski, M Akmal et al (1997) A longitudinal study on the effect of nifedipine therapy and its discontinuation on [Ca2+] i and proliferation of B lymphocytes of dialysis patients. Am J Kidney Dis 29(2), 233-238.
33.
JM Alexiewicz, M Smogorzewski, SK Gill et al (1997) Time course of the effect of nifedipine therapy and its discontinuation on [Ca2+] i and phagocytosis of polymorphonuclear leukocytes from hemodialysis patients. Am J Nephrol 17(1), 12-16.##.

comments